Although targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy,
clinical benefit with OXPHOS inhibitors has yet to be achieved. Here we advanced IACS …

Understanding the endogenous mechanisms regulating resolution of pain may identify
novel targets for treatment of chronic pain. Resolution of chemotherapy-induced peripheral …

Chemotherapy-induced peripheral neuropathy (CIPN) is a major long-lasting side effect of
some chemotherapy drugs, which threatens cancer survival rate. CIPN mostly affects …

Tricyclic antidepressants (TCAs), such as desipramine (DMI), are effective at managing
neuropathic pain symptoms but often take several weeks to become effective and also lead …

The information provided from the papers reviewed here about the role of epigenetics in
chronic craniofacial neuropathic pain is critically important because epigenetic …

Peripheral neuropathic pain induced by the chemotherapeutic cisplatin can persist for
months to years after treatment. Histone deacetylase 6 (HDAC6) inhibitors have therapeutic …

Chemotherapy is often dose limiting due to the emergence of a debilitating neuropathy. IL-
10 and IL-4 are protective against peripheral neuropathy, yet the contribution by CD4+ T …

A colloidal synthesis' proof-of-concept based on the Bligh–Dyer emulsion inversion method
was designed for integrating into lipid nanoparticles (LNPs) cell-permeating DNA antisense …

The crosstalk between breast cancer cells and tumor associated macrophages (TAMs)
greatly contributes to tumor progression and immunosuppression. In this work, cat eye …

In their letter 1, Médard and Sheltzer express concern regarding potential off-target effects
and associated toxicity when using the HDAC6 inhibitor ricolinostat as anticancer therapy …